Showing posts with label Statins. Show all posts
Showing posts with label Statins. Show all posts

Tuesday, August 20, 2013

Statins Plus Certain Antibiotics May Set Off Toxic Reaction: Study

Harmful effects in older patients include muscle, kidney damage, researchers sayIt may be contributing to growing problem of

By Steven Reinberg

HealthDay Reporter

MONDAY, June 17 (HealthDay News) -- Doctors should avoid ordering certain antibiotics for older patients who take cholesterol-lowering statin drugs, such as Lipitor, Canadian researchers say.

Statins, which are taken by many millions of people, don't mix well with the antibiotics clarithromycin or erythromycin, according to a study, published in the June 18 issue of the Annals of Internal Medicine.

These two commonly used antibiotics inhibit the metabolism of statins and increase statin concentration in the blood, which can cause muscle or kidney damage, and even death, the researchers said.

"These drugs do interact and cause difficulties for patients," said lead researcher Dr. Amit Garg, a professor in the department of epidemiology and biostatistics at the University of Western Ontario in London, Ontario.

These adverse reactions are rare, Garg added. "Most people will be fine," he said. "But at a population level, hundreds of preventable hospitalizations are occurring."

For someone taking a statin, the study suggests that substituting a different antibiotic -- azithromycin -- is safer because it doesn't interfere with the metabolism of statins.

Another strategy is to stop the statin until the antibiotic course is finished, Garg said.

The study of more than 144,000 statin users over the age of 65 compared those prescribed clarithromycin or erythromycin with those taking azithromycin.

In terms of absolute risk, the odds of kidney damage increased 26 percent among people who took clarithromycin or erythromycin and statins compared with patients who took azithromycin with statins.

Also, hospitalizations for muscle damage (a condition called rhabdomyolysis) and deaths were slightly higher -- 0.02 percent and 0.25 percent, respectively -- in the clarithromycin or erythromycin groups compared to the azithromycin group, the study authors found.

Dr. Gregg Fonarow, a spokesman for the American Heart Association, said patients should not stop taking statins, which are known to prevent heart disease. Instead, doctors should prescribe another antibiotic, he suggested.

"It is well documented that certain medications that inhibit the liver enzyme cytochrome P450 isoenzyme 3A4 can increase the drug level of statin medications," said Fonarow, a professor of cardiology at the University of California, Los Angeles. "Nevertheless, large-scale randomized clinical trials and clinical effectiveness studies have demonstrated [that] the benefits of statin therapy in reducing fatal and nonfatal cardiovascular events outweigh the potential risks."

The study data included more than 73,000 patients prescribed clarithromycin, about 3,200 prescribed erythromycin and more than 68,000 people who took azithromycin. Almost three-quarters of the statin users were taking atorvastatin (Lipitor). The other commonly used statins were simvastatin (Zocor) and lovastatin (Altoprev, Mevacor).

Clarithromycin and erythromycin are often prescribed for respiratory illness such as pneumonia. Previously, the U.S. Food and Drug Administration warned that statins don't interact well with these and certain other drugs used to treat HIV and hepatitis.

The study authors noted that younger patients are less likely than older adults to experience serious side effects from drug interactions.


View the original article here

Thursday, May 30, 2013

Could Statins Raise Diabetes Risk?

Some popular brands associated with high blood sugar levels in study, but odds of problems are lowNesina, Kazano and Oseni each contain a new

By Margaret Farley Steele

HealthDay Reporter

THURSDAY, May 23 (HealthDay News) -- Certain statins -- the widely used cholesterol-lowering drugs -- may increase your chances of developing type 2 diabetes, a new study suggests.

The risk was greatest for patients taking atorvastatin (brand name Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor), the study said.

Focusing on almost 500,000 Ontario residents, researchers in Canada found that the overall odds of developing diabetes were low in patients prescribed statins. Still, people taking Lipitor had a 22 percent higher risk of new-onset diabetes, Crestor users had an 18 percent increased risk and people taking Zocor had a 10 percent increased risk, relative to those taking pravastatin (Pravachol), which appears to have a favorable effect on diabetes.

Physicians should weigh the risks and benefits when prescribing these medications, the researchers said in the study, which was published online May 23 in the journal BMJ.

This does not, however, mean that patients should stop taking their statins, the experts said. The study also showed only an association between statin use and higher risk of diabetes; it did not prove a cause-and-effect relationship.

"While this is an important study evaluating the relationship between statins and the risk of diabetes, the study has several flaws that make it difficult to generalize the results," said Dr. Dara Cohen, a professor of medicine in the department of endocrinology, diabetes and bone disease at the Icahn School of Medicine at Mount Sinai in New York City. "There was no data regarding weight, ethnicity and family history -- all important risk factors for the development of diabetes."

Cohen added that there was no information on the patients' cholesterol and blood sugar levels, and that higher-risk patients might automatically be prescribed stronger statins such as Lipitor, Crestor and Zocor.

Finnish doctors wrote in an accompanying editorial that this potential risk should not stop people from taking statins.

"The overall benefit of statins still clearly outweighs the potential risk of incident diabetes," researchers from the University of Turku said. Statins have been proven to reduce heart problems, they said, adding that the medications "play an important role in treatment."

Other statins did perform more favorably than Lipitor, Crestor and Zocor in terms of diabetes, the research found.

"Preferential use of pravastatin and potentially fluvastatin ... may be warranted," the study authors said in a journal news release, adding that Pravachol may even be beneficial to patients at high risk of diabetes. Fluvastatin (Lescol) was associated with a 5 percent decreased risk of diabetes and lovastatin (Mevacor) a 1 percent decreased risk.

In previous research, Crestor was associated with a 27 percent higher risk of diabetes, while Pravachol was linked to a 30 percent lower risk.

For this study, the researchers used patient information from three Canadian databases on 66-year-old men and women who were newly prescribed statins and followed for up to five years. Lipitor accounted for more than half of all new statin prescriptions, followed by Crestor, Zocor, Pravachol, Mevacor and Lescol.

The researchers said between 162 and 407 patients would have to be taking statins of various kinds for one extra patient to develop diabetes.

Results were similar for patients already diagnosed with heart disease and those taking statins to prevent it. Older patients using Lipitor and Zocor were at an increased risk regardless of dose, the researchers found.

People with type 2 diabetes have higher than normal blood sugar levels because their bodies don't make or properly use insulin. The researchers said it is possible that certain statins impair insulin secretion and inhibit insulin release, which could help explain the findings.


View the original article here

Tuesday, May 7, 2013

TV Ads for Statins May Drive Overtreatment

Title: TV Ads for Statins May Drive Overtreatment
Category: Health News
Created: 3/8/2013 10:35:00 AM
Last Editorial Review: 3/8/2013 12:00:00 AM

View the original article here